<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40992803</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1876-7605</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>JACC. Cardiovascular interventions</Title><ISOAbbreviation>JACC Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.</ArticleTitle><Pagination><StartPage>2226</StartPage><EndPage>2237</EndPage><MedlinePgn>2226-2237</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcin.2025.07.035</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-8798(25)02124-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal percutaneous coronary intervention (PCI) strategy in ST-segment elevation myocardial infarction (STEMI)-related cardiogenic shock and multivessel disease remains uncertain.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to investigate the association between PCI strategy and outcomes in STEMI-related cardiogenic shock and multivessel disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This exploratory substudy of the DanGer Shock (Danish-German Cardiogenic Shock) multicenter trial included patients with STEMI-related cardiogenic shock and multivessel disease, excluding comatose patients resuscitated from cardiac arrest. Multivessel disease was defined by &#x2265;1 nonculprit angiographic stenosis &#x2265;70%. Patients with an isolated left main culprit were excluded. The planned PCI strategy was registered before randomization. All analyses were performed according to as-treated PCI strategy (immediate multivessel PCI or culprit-only PCI). The primary outcome was all-cause mortality within 180 days; secondary outcomes included renal replacement therapy and acute kidney injury.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 355 patients included in the DanGer Shock trial, 221 (72%) had multivessel disease; of these, 118 (53%) were treated with culprit-only PCI and 103 (47%) with immediate multivessel PCI. The median pre-PCI SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores were 28 (Q1-Q3: 22-32) and 29 (Q1-Q3: 22-34), respectively. Chronic total occlusion PCI was performed in 6 of 103 patients (6%) treated with immediate multivessel PCI. All-cause mortality was 72 (61%; 95% CI: 52%-70%) in the culprit-only group and 52 (50%; 95% CI: 41%-60%) in the immediate multivessel PCI group (adjusted OR: 0.40; 95% CI: 0.19-0.83) over a median follow-up period of 45 days (Q1-Q3: 2-180 days). Immediate multivessel PCI was not associated with the secondary outcomes. There was no interaction according to randomization allocation and PCI strategy (P = 1.00).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immediate multivessel PCI was associated with 60% lower odds of all-cause mortality compared with culprit-only PCI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marquard</LastName><ForeName>Jasmine M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: jasmine.melissa.marquard@regionh.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beske</LastName><ForeName>Rasmus P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassager</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Lisette O</ForeName><Initials>LO</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiskj&#xe6;r</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangner</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polzin</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany; Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit&#xe9;, Campus Benjamin Franklin, Berlin, Germany; Deutsches Zentrum f&#xfc;r Herz-Kreislauf-Forschung, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panoulas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Nikos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Heart Center Trier, Krankenhaus der Barmherzigen Br&#xfc;der, Trier, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmvang</LastName><ForeName>Lene</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf8;nborg</LastName><ForeName>Jacob T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udesen</LastName><ForeName>Nanna L J</ForeName><Initials>NLJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junker</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terkelsen</LastName><ForeName>Christian J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Heart Center Dresden, University Hospital, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zako</LastName><ForeName>Saif</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital D&#xfc;sseldorf, Medical Faculty of the Heinrich Heine University D&#xfc;sseldorf, D&#xfc;sseldorf, Germany; Cardiovascular Research Institute D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Memisevic</LastName><ForeName>Nedim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Cardiology, Angiology and Intensive Medical Care, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantinou</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, Harefield Hospital, Harefield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schrage</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Center for Population Health Research, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center, University Clinic Hamburg-Eppendorf, Center for Population Health Research, Hamburg, Germany; Department of Cardiology, Zealand University Hospital, Roskilde and Nyk&#xf8;bing Falster, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Cardiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf8;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DanGer Shock Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Cardiovasc Interv</MedlineTA><NlmUniqueID>101467004</NlmUniqueID><ISSNLinking>1936-8798</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="Y">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072657" MajorTopicYN="Y">ST Elevation Myocardial Infarction</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">STEMI</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">multivessel PCI</Keyword><Keyword MajorTopicYN="N">multivessel disease</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures This trial was funded by research grants from the Danish Heart Foundation (NO 12-04-R90-A3960-22700) and Abiomed Johnson &amp; Johnson MedTech. Dr Hassager has received institutional research grants from the Novo Nordisk Foundation, the Lundbeck Foundation, and the Danish Heart Foundation. Dr Jensen has received a travel grant from Boston Scientific. Dr Eiskj&#xe6;r has received institutional research grants from the Novo Nordisk Foundation and Independent Research Fund Denmark, not related to this topic; and has received speaker fee from Novartis. Dr Mangner has received research and educational grants from Abiomed to his institution, outside the submitted work; has received an educational grant from Boston Scientific to his institution, outside the submitted work; and has received personal fees from Edwards Lifesciences, Medtronic, Biotronik, Novartis, Sanofi Genzyme, AstraZeneca, Pfizer, Daiichi-Sankyo, Abbott Laboratories, Abiomed, B. Braun, and Boston Scientific, outside the submitted work. Dr Polzin has received institutional research grants and personal speaker honoraria from Abiomed. Dr Schulze has received grants from Boehringer Ingelheim, Abiomed, Edwards Lifesciences, CytoSorbents, and Boston Scientific; and has received consulting fees and/or honoraria from Bayer, AstraZeneca, Daiichi-Sankyo, Novartis, Actelion, Roche, Sanofi, Pharmacosmos, Medtronic, Thoratec, Boehringer Ingelheim, Heartware, Coronus, Abbott Laboratories, Boston Scientific, St. Jude Medical, Abiomed, and DGK; and has performed trial committee work for Abbott and Abiomed. Dr Skurk has received speaking fees from Abiomed. Dr Nordbeck has received speaker honoraria from Abiomed, Bayer Healthcare, Boehringer Ingelheim, Daiichi-Sankyo Europe, and Pfizer. Dr Zimmer has had speaking engagements for and serves on the scientific advisory board for Abiomed. Dr Sch&#xe4;fer has received honoraria from Abiomed, ZOLL Medical, AstraZeneca, Amgen, Bristol Myers Squibb, Pfizer, Daiichi-Sankyo, Eli Lilly, and Boehringer Ingelheim; and has received institutional grants from Abiomed and Daiichi-Sankyo. Dr Werner is a consultant for Abiomed, Boehringer Ingelheim, SockWave Medical, and Protembis; and has received travel grants and speaking fees from Abiomed. Dr Holmvang has received a travel grant from Boston Scientific. Dr L&#xf8;nborg has received an advisory board fee, an unrestricted grant, and a speaking fee from Boston Scientific; and has received a speaking fee from Abbott Laboratories. Dr Terkelsen has received research grants from Novo Nordisk and the Danish Heart Foundation not related to this topic; has received unrestricted research grants from Meril and Terumo not related to this topic; and has received lecture and proctor fees from Meril and Terumo not related to this topic. Dr Linke has received consulting and speaking honoraria from Abbott Laboratories, Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Corvia, Daiichi-Sankyo Europe, Edwards Lifesciences, Medtronic, Novartis, and Pfizer; and has stock options with Pi-Cardia and Transverse Medical. Dr Clemmensen has had previous or current involvement in research contracts, consulting, and Speakers Bureaus and has received research and educational grants from Abbott, Abiomed, AliveCor, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CeleCor, Daiichi-Sankyo, Eli Lilly, Evolva, Fibrex, Idorsia, IQVIA, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Philips, Regado, Sanofi, Searle, Servier, and ViFor Pharma. Dr Panoulas has received consulting fees, honoraria, and an educational grant from Abiomed Johnson &amp; Johnson. Dr Schrage has received speaking fees from Abbott Laboratories, Abiomed, AstraZeneca, and Inari; and has received research support from Abiomed, Deutsche Forschungsgemeinschaft, Deutsches Zentrum f&#xfc;r Herz-Kreislaufforschung, the University of Hamburg, and Else Kr&#xf6;ner-Fresenius Stiftung, outside the submitted work. Dr M&#xf8;ller has received institutional research grants from Abiomed and the Novo Nordisk Foundation; and is an advisory board member for Boston Scientific. Dr Engstr&#xf8;m has received speaking fees from Abbott Vascular, Boston Scientific, and Bayer; has received advisory board fees from Abbott and Novo Nordisk; and has participated in data and safety monitoring for the IN-FINITY trial and the PURE-TAVI trial. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Jacob Eifer</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jensen</LastName><ForeName>Lisette Okkels</ForeName><Initials>LO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Junker</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tange Veien</LastName><ForeName>Karsten</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Udesen</LastName><ForeName>Nanna Louise Junker</ForeName><Initials>NLJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassager</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engstr&#xf8;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmvang</LastName><ForeName>Lene</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kjaergaard</LastName><ForeName>Jesper</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Rikke</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf8;nborg</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fryldand</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paulin Beske</LastName><ForeName>Rasmus</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boesgaard</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eiskj&#xe6;r</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christensen</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Evald H&#xf8;j</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terkelsen</LastName><ForeName>Christian Juhl</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linke</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woitek</LastName><ForeName>Felix J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hommel</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangner</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polzin</LastName><ForeName>Amin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Westenfeld</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulze</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moebius-Winkler</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skurk</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nordbeck</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clemmensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Westermann</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panoulas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werner</LastName><ForeName>Nicos</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40992803</ArticleId><ArticleId IdType="doi">10.1016/j.jcin.2025.07.035</ArticleId><ArticleId IdType="pii">S1936-8798(25)02124-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>